Внесок користувача
- 18:13, 30 листопада 2016 (різн. • історія) . . (+3578) . . Н Added scientific studies used the virus entry inhibitor enfuvirtide (Fuzeon) and the bN-MAb 4E10, equally of which focus on web-sites in gp41 such as the membrane proximal exterior location (Створена сторінка: This end result was somewhat stunning, considering that the glycans acknowledged by PG9 (N156 and N160) occur in comparatively close proximity to the V1 glycans...) (поточна)
- 14:52, 30 листопада 2016 (різн. • історія) . . (+3762) . . Н Values in bold represent significant neutralization titers that are at least three times greater than those observed against the negative control (Створена сторінка: The neutralizing antibody titer (IC50) is described as the reciprocal of the plasma dilution that generates a 50% inhibition in focus on cell infection. Values...) (поточна)
- 14:51, 29 листопада 2016 (різн. • історія) . . (+446) . . м The raw data from the QSTAR ELITE were analyzed with MASCOT Daemon software (version 2.2.2, Matrix Science) using a local Mascot server (поточна)
- 14:47, 29 листопада 2016 (різн. • історія) . . (+3710) . . Н The raw data from the QSTAR ELITE were analyzed with MASCOT Daemon software (version 2.2.2, Matrix Science) using a local Mascot server (Створена сторінка: The information had been searched towards the SwissProt Rattus database with additional dimethyl masses. The following parameters were set for the Mascot lookup...)
- 14:14, 29 листопада 2016 (різн. • історія) . . (+3482) . . Н All of the procedures involving the animals conformed to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and was approved by the Committee on Ethics in the Care and Use (Створена сторінка: The retinal I/R injuries was induced as previously described [19, twenty]. The duration of ischemia was sixty min. Following the ischemia, the reflow of the ret...) (поточна)
